Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?

Core Viewpoint - The merger agreement between NLS Pharmaceutics and Kadimastem will result in Kadimastem investors acquiring 85% of the combined company's stock, with the new entity operating under the Kadimastem name [1] Group 1: Merger Details - NLS Pharmaceutics will be acquired by a wholly-owned subsidiary of Kadimastem, leading to a significant ownership shift [1] - The merger is expected to be executed in September, with a closing date anticipated by the end of the year [3] - Following the merger, nearly all members of the NLS Pharmaceutics board and executive team will depart, except for one [6] Group 2: Stock Market Impact - NLS Pharmaceutics stock has seen a substantial increase of 47.8% as of Monday morning following the merger announcement [7] - Heavy trading activity has been noted, with over 98 million shares being traded, significantly higher than the average daily volume of about 10 million shares [4][5] Group 3: Future Developments - The combined company will continue to develop NLS Pharmaceutics' Dual Orexin Agonist platform and Kadimastem's allogeneic cell products [6] - NLS shareholders will have the opportunity to benefit from the equity of the merged company and the value of legacy assets through a contingent value rights agreement [7]